about
European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHDNeuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognitionSingle exposure of dopamine D1 antagonist prevents and D2 antagonist attenuates methylphenidate effectTreating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulantsGuanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorderAn open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness.Nonmedical use of prescription stimulants among college students: associations with attention-deficit-hyperactivity disorder and polydrug use.Open-label dose optimization of methylphenidate modified release long acting (MPH-LA): a post hoc analysis of real-life titration from a 40-week randomized trial.Does pharmacotherapy for attention-deficit/hyperactivity disorder predict risk of later major depression?An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adultsReinforcing effects of methamphetamine in an animal model of attention-deficit/hyperactivity disorder--the spontaneously hypertensive ratImpact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial.Population pharmacokinetic/pharmacodynamic modeling of guanfacine effects on QTc and heart rate in pediatric patients.Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine saltsSubjective effects, misuse, and adverse effects of osmotic-release methylphenidate treatment in adolescent substance abusers with attention-deficit/hyperactivity disorder.Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe.Bupropion SR in adults with ADHD: a short-term, placebo-controlled trial.Pharmacokinetics of coadministration of guanfacine extended release and methylphenidate extended release.Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate.Inattention symptoms predict level of depression in early childhood.Atomoxetine: a novel treatment for child and adult ADHDA review of co-morbid depression in pediatric ADHD: etiology, phenomenology, and treatment.Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology.The Impact of Methylphenidate on Motor Performance in Children with both Attention Deficit Hyperactivity Disorder and Developmental Coordination Disorder: A Randomized Double-Blind Crossover Clinical Trial.Prolonged bradycardia and hypotension following guanfacine extended release overdose.
P2860
Q21260332-8A2C885B-6AE3-4413-9266-0C5287490509Q24614080-3785F119-3AEE-4405-8EC0-32CCB5704375Q28275563-5EF161B4-E776-4A95-8B24-9D69A1AD872DQ33746664-D65D4BF6-5762-4C21-AE31-A644D39C88EAQ33782856-795DC1D5-CC2C-47BE-A7B2-D1A099B54E9FQ33819917-924B6F38-FE74-4B45-88EB-BF8ABF41CBA8Q34006010-B1AA3EBA-061D-4F3C-A789-7064633E6AFAQ34085116-6BA84996-E4FF-4DDA-937B-B304E6DECD15Q34112070-11FD8444-846D-46CC-8F28-79DDCCE99772Q34220004-708557B2-5E42-48E8-B5F3-D80BA9D831B1Q34468086-FB14BF13-060B-4D75-98EF-C555228F6DA8Q35151922-AC6C008F-C399-45CA-80F8-422B21F4EBFAQ35318113-262C8CDC-11A8-449A-9889-FD6D8D53C1C1Q35625891-6F19A239-A62E-405A-9CD5-5E7E9518E7D4Q35625911-DF0CA49E-57A3-4FA8-BB83-B211EB8D71E6Q36026845-350D3058-19D4-44BE-94DB-BD77627AD2F7Q36446854-6F947DA0-8D3E-4ECE-84BB-C92907D3543EQ36703814-3C566860-9DDD-4EAA-84B1-A0F8DA6D4CEDQ36767738-6EA1D06F-D725-46F4-ABA4-8026FD540B8DQ36947618-F7049E7F-A707-44DB-9637-10B6491F5C43Q37133277-F7DA7663-6B6E-4106-AE57-FB678A567F29Q37166161-9C17531C-AB78-4087-8625-CDD69AA790E6Q37235736-EF167A0B-A355-43E9-9F50-E8C3BA7AD3CEQ37300068-4CE58A91-6456-4240-A6B9-A6117310AB5FQ41098335-844E66AC-1A86-4AB9-BD18-0823E251D97FQ42951634-940301EE-DF37-4AFE-BB32-458553C808B6
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The stimulants revisited.
@ast
The stimulants revisited.
@en
The stimulants revisited.
@nl
type
label
The stimulants revisited.
@ast
The stimulants revisited.
@en
The stimulants revisited.
@nl
prefLabel
The stimulants revisited.
@ast
The stimulants revisited.
@en
The stimulants revisited.
@nl
P1476
The stimulants revisited
@en
P2093
P304
573-603, viii
P356
10.1016/S1056-4993(18)30108-1
P577
2000-07-01T00:00:00Z